Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Related Keywords

Italy ,Poland ,Warsaw ,L67 ,Hendrik Nogai ,Kamil Sitarz ,European Union Clinical Trial Regulation ,Menarini Group ,Warsaw Stock Exchange ,Development Plan ,Chief Medical Officer ,Ryvu Therapeutics ,Chief Operating Officer ,Competent Authorities ,Ethics Committees ,